Prudential Financial Inc.’s holdings in Supernus Pharmaceuticals were worth $2,374,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals ...

Supernus Pharmaceuticals stock opened at $33.05 on Monday. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a fifty day simple moving average of ...

NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals ...

The results square up with those produced by Supernus’ Qelbree, “which showed a similar 3.8-point placebo-normalized reduction in AISRS at Week 6,” William Blair analyst Myles Minter ...

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...